141 related articles for article (PubMed ID: 20717111)
1. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E; Massard C; Armand JP; Tillier C; Hartog V; Brega NM; Countouriotis AM; Ruiz-Garcia A; Soria JC
Br J Cancer; 2010 Sep; 103(7):993-1000. PubMed ID: 20717111
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
9. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Hamberg P; Steeghs N; Loos WJ; van de Biessen D; den Hollander M; Tascilar M; Verweij J; Gelderblom H; Sleijfer S
Br J Cancer; 2010 Jun; 102(12):1699-706. PubMed ID: 20485286
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Hoff PM; Wolff RA; Bogaard K; Waldrum S; Abbruzzese JL
Jpn J Clin Oncol; 2006 Feb; 36(2):100-3. PubMed ID: 16449240
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Martin LK; Bekaii-Saab T; Serna D; Monk P; Clinton SK; Grever MR; Kraut EH
Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Okamoto I; Shimizu T; Miyazaki M; Tsurutani J; Ichikawa Y; Terashima M; Takeda M; Fumita S; Ohki E; Kimura N; Hashimoto J; Nakagawa K
Invest New Drugs; 2012 Apr; 30(2):639-46. PubMed ID: 20960028
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
